Assignee
EIGER BIOPHARMACEUTICALS INC
US·14 granted patents·19 pending applications·68 citations·filing 2015–2023
Top patents by PatentIndex Score
33 records- 0196US11311519B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2020·Granted Apr 26, 2022·6 cites·21 claims
- 0295US11793793B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2022·Granted Oct 24, 2023·3 cites·35 claims
- 0395US10828283B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2018·Granted Nov 10, 2020·10 cites·20 claims
- 0495US10076512B2Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2016·Granted Sep 18, 2018·12 cites·18 claims
- 0594US11738086B2Methods of using buffered formulations of exendin (9-39)EIGER BIOPHARMACEUTICALS INC·Filed 2021·Granted Aug 29, 2023·5 cites·26 claims
- 0694US11517532B2Methods of treating hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2020·Granted Dec 6, 2022·3 cites·23 claims
- 0794US11116820B2Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivativesEIGER BIOPHARMACEUTICALS INC·Filed 2020·Granted Sep 14, 2021·3 cites·14 claims
- 0893US12029819B2Pharmaceutical compositions comprising lonafarnib and ritonavirEIGER BIOPHARMACEUTICALS INC·Filed 2022·Granted Jul 9, 2024·1 cites·20 claims
- 0992US10653753B2Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivativesEIGER BIOPHARMACEUTICALS INC·Filed 2017·Granted May 19, 2020·10 cites·17 claims
- 1089US11020484B2Buffered formulations of exendin (9-39)EIGER BIOPHARMACEUTICALS INC·Filed 2017·Granted Jun 1, 2021·8 cites·30 claims
- 1185US10835496B2Pharmaceutical compositions comprising lonafarnib and ritonavirEIGER BIOPHARMACEUTICALS INC·Filed 2016·Granted Nov 17, 2020·4 cites·24 claims
- 1282US2024316156A1Compositions of exendin-4 derivativesEIGER BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1381US10588880B2Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitisEIGER BIOPHARMACEUTICALS INC·Filed 2017·Granted Mar 17, 2020·1 cites·20 claims
- 1479US2024042035A1Buffered Formulations Of Exendin (9-39)EIGER BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1573US2021369814A1Compositions of exendin-4 derivativesEIGER BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1672US10953072B2Treatment of hepatitis delta virus infection with interferon lambdaEIGER BIOPHARMACEUTICALS INC·Filed 2017·Granted Mar 23, 2021·2 cites·24 claims
- 1767US2017312373A1Method for enhanced uptake of viral vectors in the myocardiumEIGER BIOPHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1864US2016263248A1Method for enhanced uptake of viral vectors in the myocardiumEIGER BIOPHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1961US2022023287A1Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2061US2024207243A1Method of treating laminopathiesEIGER BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2160US11571403B2Methods for the treatment of non-alcoholic steatohepatitisEIGER BIOPHARMACEUTICALS INC·Filed 2020·Granted Feb 7, 2023·0 cites·48 claims
- 2259US2024108691A1Treatment of hepatitis e virus infection with interferon lambdaEIGER BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2358US2024307501A1Treatment of congenital hyperinsulinism with avexitideEIGER BIOPHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2455US2023201308A1Treatment of coronavirus infection with interferon lambdaEIGER BIOPHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2554US2021121454A1Method of treating laminopathiesEIGER BIOPHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2653US2024082360A1Methods to treat hepatitis delta viral infectionsEIGER BIOPHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2752US2021267961A1Method of treating laminopathiesEIGER BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2852US2018338993A1Treatment of hepatitis delta virus infectionEIGER BIOPHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2950US2021187073A1Treatment of hepatitis delta virus infection with interferon lambdaEIGER BIOPHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3049US2021369693A1Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitisEIGER BIOPHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3148US2023285510A1Treatment of coronavirus infection with interferon lambdaEIGER BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3243US2021338780A1Avexitide for the treatment of hyperinsulinemic hypoglycemiaEIGER BIOPHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3334US2017281611A1Quinolines and their use for treating endoplasmic reticulum stress-caused diseasesEIGER BIOPHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EIGER BIOPHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →